title: Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
abstract: Tuberous sclerosis complex (TSC) is a hamartoma syndrome in which brain, renal, and lung tumors develop and cause both morbidity and death. Loss of either TSC1 or TSC2 in TSC hamartomas leads to activation of mTORC1. Rapamycin and related drugs have been shown to have clinical benefit for these tumors in patients with TSC and those with sporadic forms of TSC-related neoplasms. However, lifelong therapy seems to be required, as tumors are not eliminated by this treatment. We examined the potential benefit of MLN0128, a novel potent mTOR ATP-competitive inhibitor, as a therapeutic strategy for renal cystadenomas that develop in A/J Tsc2(+/-) mice. Rapamycin given by intraperitoneal injection at 3 mg/kg 3 times per week, and MLN0128 given by gavage at 0.75 mg/kg 5 times per week had equivalent effects in suppressing tumor development during a 4-week treatment period, with an approximate 99% reduction in microscopic tumor cell volume. Marked reduction in activation of mTOR complex (mTORC)1 and blockade of cell growth was seen with both drugs, whereas only MLN0128 treatment had effects in blocking mTORC2 and 4EBP1 phosphorylation. However, when either drug was discontinued and mice were observed for two additional months, there was dramatic recovery of tumor growth, with extensive proliferation. Hence, longlasting tumor growth control is not achieved with transient treatment with either drug, and MLN0128 and rapamycin have equivalent therapeutic benefit in this mouse model. Differences in side-effect profiles might make MLN0128 more attractive for treatment of patients with TSC-related tumors, but will require additional study in humans.
authors: Division of Translational Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
authors: Yanan
authors: Y
authors: Guo
authors: David J
authors: DJ
authors: Kwiatkowski
mesh_terms: D000818:Animals; D001583:Benzoxazoles / Q000494:pharmacology*; D048708:Cell Growth Processes / Q000187:drug effects; D003537:Cystadenoma / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000076222:Mechanistic Target of Rapamycin Complex 1; D051379:Mice; D046912:Multiprotein Complexes / Q000037:antagonists & inhibitors / Q000378:metabolism; D010766:Phosphorylation; D011743:Pyrimidines / Q000494:pharmacology*; D015398:Signal Transduction; D020123:Sirolimus / Q000494:pharmacology*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014402:Tuberous Sclerosis / Q000188:drug therapy* / Q000473:pathology; D000225:Adenine / Q000031:analogs & derivatives
chemical_list: D001583:Benzoxazoles; D000076222:Mechanistic Target of Rapamycin Complex 1; D046912:Multiprotein Complexes; D011743:Pyrimidines; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; C546843:mTOR protein, mouse; C572449:sapanisertib; D000225:Adenine
references: N Engl J Med. 2008 Jan 10;358(2):200-3
references: 18184971
references: Chest. 2008 Feb;133(2):507-16
references: 18252917
references: Immunol Rev. 2012 Sep;249(1):43-58
references: 22889214
references: PLoS One. 2012;7(2):e31900
references: 22363765
references: N Engl J Med. 2011 Apr 28;364(17):1595-606
references: 21410393
references: Clin Cancer Res. 2012 May 1;18(9):2603-12
references: 22407832
references: J Clin Invest. 1999 Sep;104(6):687-95
references: 10491404
references: J Transl Med. 2010 Feb 10;8:14
references: 20146790
references: Mol Cell. 2012 Aug 24;47(4):535-46
references: 22795129
references: Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17414-9
references: 18955708
references: Kidney Int. 2004 Sep;66(3):924-34
references: 15327383
references: Nat Rev Mol Cell Biol. 2011 Jan;12(1):21-35
references: 21157483
references: Ann Neurol. 2006 Mar;59(3):490-8
references: 16453317
references: Biochem J. 2008 Jun 1;412(2):179-90
references: 18466115
references: N Engl J Med. 2006 Sep 28;355(13):1345-56
references: 17005952
references: Eur Respir J. 2006 May;27(5):1056-65
references: 16707400
references: N Engl J Med. 2010 Nov 4;363(19):1801-11
references: 21047224
references: Curr Med Chem. 2011;18(20):2995-3014
references: 21651476
references: N Engl J Med. 2008 Jan 10;358(2):140-51
references: 18184959